CardioAI

What CardioAI does

Cardio.AI, operated by Latvia-incorporated XOresearch SIA (Reg. No. 50103912671), provides an AI-powered ECG analysis platform certified as an EU MDR 2017/745 Class IIa medical device software. The platform serves healthcare providers (clinics and hospitals in Ukraine and the broader Eastern European region), cardiologists and ECG technicians, corporate clients seeking employee cardiac screening, and research organizations conducting cardiology studies. The company is led by CEO Maksym Diachenko, Product Owner Pavlo Karpenko, and Head of BDM Yuliana Nemiska, with a cross-functional team of cardiologists, developers, data scientists, and engineers that has been focused on cardiac AI for more than five years.

The core Cardio.AI Platform is built on deep learning using generative networks with a high-performance analytical backend, trained on 5 million+ cardiologist-validated heartbeats. It supports any lead configuration with ECG recordings up to 35 days, processes the EDF, BDF, SCP, and ZHR formats, and classifies 80+ beat and rhythm abnormalities with >95% noise separation accuracy and >98% accuracy on key arrhythmias. Processing time is approximately 30 seconds per 24-hour ECG, reducing technician time to under 10 minutes per 1–7 day record. The platform is validated with nine ECG device manufacturers (Bittium, Cortium, LifeSignals, Livetec, Philips, Biomedical Instruments, BTL, ScottCare Holter, Amedtec) and is complemented by a Remote Cardiac Monitoring Service bundling LifeSignals 2-channel single-use CE/FDA biosensors, a Corporate Cardiology Check-Up Service, and a Research ECG Monitoring Service.

Cardio.AI monetizes through four streams: (1) SaaS platform access on annual quote-based subscriptions for self-serving clinics and technicians, (2) end-to-end ECG reporting services bundled with consumable biosensors on multi-year contracts, (3) corporate cardiac screening on unit pricing, and (4) recurring revenue from biosensor consumables. Go-to-market combines direct enterprise sales, product-led growth via a public demo (web.cardio.ai/orgs/pub_demo), API-based distribution through validated device partners, and event-driven demand generation (VivaTech 2022, Ukrainian Israeli Innovation Summit, U Tomorrow Summit). The company reports 40+ partner clinics in Ukraine, 10,000+ end-to-end reports delivered, and 20,000+ ECG recordings analyzed. EU MDR certification (valid through October 2030) and ISO 13485:2016 certification position the platform for EU expansion, with FDA clearance expected in 2026 to unlock the US market.

Name

CardioAI

Legal name

XOresearch SIA

Website

https://cardio.ai

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Cardio.AI (operated by Latvia-incorporated XOresearch SIA) provides an EU MDR Class IIa-certified AI platform for automated ECG interpretation, serving clinics, hospitals, cardiologists, corporate clients, and research organizations in Eastern Europe with cloud-based arrhythmia detection and remote cardiac monitoring services.

Ownership category

akta.pro rank

Product category

Cardiac AI Software (ECG Analysis)

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372)

akta.pro industry

PRIMARYHLALAGAB

Cardiology Telemedicine Platforms

Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

SECONDARYHLALAFAA

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)

Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

SECONDARYHLALAJAD

AI Triage & Clinical Decision Support (CDS) Platforms

Healthcare & Life Sciences/Telehealth Platforms/Urgent Care & On-Demand Triage Telehealth Platforms

Keywords

• ECG analysis software
• Cardiac AI platform
• Arrhythmia detection
• Remote cardiac monitoring
• Holter reporting service

Headquarters

HQ city

Kyiv

HQ country

Ukraine

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Platform Software as a Service (SaaS): Cardio.AI provides cloud-based access to the ECG analytical platform for cardiac analysis designed for ECG technicians and cardiologists. Clinics can access the platform 24/7 to process ECG data. The platform can also integrate with the client's own ECG monitoring devices. Pricing is quote-based, likely structured as a subscription or per-report model.
2. End-to-End ECG Reporting Services: Full outsourcing solution where Cardio.AI's team provides complete extended ECG reporting services. Includes setup support, staff training, consumables (ECG biosensors), automated analysis, and rapid finalized reports with full physician review. A finalized clinician-reviewed report is delivered within one working day.
3. ECG Biosensor Consumables: LifeSignals 2-Channel ECG Wearable Biosensors are provided as consumables to partner clinics. The biosensors are single-use devices supplied alongside the monitoring service. ECG biosensors are provided as consumables with no prepayment required.
4. Corporate Cardiac Check-Up Services: Cardio.AI offers corporate cardiology check-up services for companies to conduct regular employee cardiac screenings. This B2B service enables early detection of heart diseases in professional environments and is delivered through partnerships with corporate clients.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Core offering

Cardio.AI operates a cloud-based, EU MDR Class IIa-certified medical device software platform that uses deep learning to automatically annotate and interpret ECG recordings of any lead configuration with durations up to 35 days. The platform is sold both as self-serve SaaS access for ECG technicians and cardiologists, and as a fully outsourced end-to-end remote cardiac monitoring service that bundles biosensors, automated analysis, and clinician-reviewed reporting. Complementary offerings include corporate cardiac check-up services and research ECG monitoring for clinical studies.

Product overview

CardioAI offers a unified product portfolio centered on the Cardio.AI Platform, a cloud-based AI-powered ECG analytical software medical device (Class IIa). The platform serves as the core product, processing ECG data from multiple validated third-party devices (Bittium, Cortium, LifeSignals, Livetec, Philips, BTL, ScottCare, Amedtec) and generating automated cardiac analysis reports. The portfolio includes supplementary service modules: Remote Cardiac Monitoring Service (end-to-end solution with LifeSignals biosensors and Telegram Bot access), Corporate Cardiology Check-Up Service (employee screening), and Research ECG Monitoring Service (clinical study support). The platform supports ECG recordings up to 35 days, detects 80+ beat/rhythm abnormalities, and delivers results in approximately 30 seconds for 24-hour ECGs.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 100% improvement in service efficiency reported by medical partners
• +9 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability5 records

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• TÜV SÜD Product Service GmbH (Notified Body 0123)coreOthers · 6 October 2025TÜV SÜD is the accredited Notified Body that certified Cardio.AI under EU MDR 2017/745 (Class IIa) and ISO 13485:2016. The dual certification validates Cardio.AI's safety, performance, and quality management systems. TÜV SÜD oversees ongoing compliance and regulatory requirements for the medical device.
• LifeSignalscoreTechnology or IntegrationLifeSignals (USA) manufactures the 2-Channel ECG Wearable Biosensor used in Cardio.AI's end-to-end cardiac monitoring service. The LifeSignals device is CE/FDA certified, single-use, waterproof, supports up to 7-day monitoring, and provides high-quality data for Cardio.AI's AI analysis. Cardio.AI bundles these biosensors as consumables with its service, eliminating the need for clinics to source ECG monitoring devices independently.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AliveCor: AliveCor provides AI-enabled ECG analysis (KardiaMobile/KardiaPro) for clinicians and patients, directly competing with Cardio.AI's core AI-ECG interpretation use case. It is the most direct comparable in AI-driven cardiac diagnostics in non-hospital settings.
• iRhythm Technologies: iRhythm's Zio long-term cardiac monitoring service combines a wearable patch with AI-driven ECG analysis and clinician-reviewed reporting, directly overlapping Cardio.AI's end-to-end monitoring service and biosensor-plus-AI model.
• Eko Health: Eko provides AI-assisted cardiac analysis (stethoscope and ECG) used by clinicians for ECG interpretation and arrhythmia detection, competing with Cardio.AI's clinical decision support functionality for cardiologists.
• Cardiologs (Philips): Cardiologs offers an AI cloud platform for ECG/Holter analysis deployed by cardiologists and technicians, with a similar SaaS go-to-market. The Philips acquisition gives it distribution muscle, but the core product is a near-mirror of Cardio.AI's analytical platform.
• UltraLinQ Healthcare Solutions: UltraLinQ provides cloud-based ECG/Holter analysis and cardiac monitoring workflows for clinics and research organizations, closely matching Cardio.AI's analyst-facing platform and clinical research use case.

Emerging players

• HeartFlow: HeartFlow applies AI to cardiac diagnostics (coronary CT-derived FFR), sharing Cardio.AI's regulatory AI-CDS posture and cardiology specialty, though focused on imaging rather than electrical cardiac signals.
• Tempus AI: Tempus applies AI to clinical data, including ECG-derived cardiovascular insights, and competes for the same cardiology AI analytics budget at large hospital systems. Different data modality but adjacent buyer and regulatory posture.

Broad incumbents

• Preventice Solutions (Boston Scientific): Preventice (BodyGuardian) delivers ambulatory cardiac monitoring with AI triage, overlapping Cardio.AI's remote Holter/event monitoring service. Acquisition by Boston Scientific provides large-scale distribution Cardio.AI lacks.
• Philips Healthcare: Philips offers a full ECG management suite (IntelliSpace, Cardiologs) and is a validated Cardio.AI partner. As a broad incumbent, it competes head-to-head in hospital cardiology informatics and could bundle against Cardio.AI in EU/US hospital deals.
• GE Healthcare (MUSE): GE Healthcare's MUSE cardiology information system manages ECG storage, analysis, and reporting at large hospital systems, directly overlapping Cardio.AI's reporting and EHR integration capabilities from a much larger installed base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@xoresearch3604
• Facebookfacebook.com/XOresearch
• LinkedInlinkedin.com/company/cardio-ai

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CardioAI